Synthesis and biological assessment of chalcone and pyrazoline derivatives as novel inhibitor for ELF3-MED23 interaction
eLife · 2024
DOI: 10.7554/elife.97051 ↗Kurz gefasst
Fachartikel in der Zeitschrift eLife, 2024. Verfasst von Soo-Yeon Hwang und 11 weiteren Autor:innen. Beteiligte Einrichtung: College of Pharmacy and Graduate School of Pharmaceutical Sciences, Ewha Womans University, Seoul, Republic of Korea. Hauptthemen laut MEDLINE: Chalcones, Transcription Factors, Stomach Neoplasms, Proto-Oncogene Proteins c-ets. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research Foundation of Korea, Korea Basic Science Institute.
Abstract (Originalsprache)
HER2 overexpression significantly contributes to the aggressive nature and recurrent patterns observed in various solid tumors, notably gastric cancers. Trastuzumab, HER2-targeting monoclonal antibody drug, has shown considerable clinical success; however, readily emerging drug resistance emphasizes the pressing need for improved interventions in HER2-overexpressing cancers. To address this, we proposed targeting the protein-protein interaction (PPI) between ELF3 and MED23 as an alternative therapeutic approach to trastuzumab. In this study, we synthesized a total of 26 compounds consisting of 10 chalcones, 7 pyrazoline acetyl, and 9 pyrazoline propionyl derivatives, and evaluated their biological activity as potential ELF3-MED23 PPI inhibitors. Upon systematic analysis, candidate compound 10 was selected due to its potency in downregulating reporter gene activity of ERBB2 promoter confirmed by SEAP activity and its effect on HER2 protein and mRNA levels. Compound 10 effectively disrupted the binding interface between the ELF3 TAD domain and the 391–582 amino acid region of MED23, resulting in successful inhibition of the ELF3-MED23 PPI. This intervention led to a substantial reduction in HER2 levels and its downstream signals in the HER2-positive gastric cancer cell line. Subsequently, compound 10 induced significant apoptosis and anti-proliferative effects, demonstrating superior in vitro and in vivo anticancer activity overall. We found that the anticancer activity of compound 10 was not only restricted to trastuzumab-sensitive cases, but was also valid for trastuzumab-refractory clones. This suggests its potential as a viable therapeutic option for trastuzumab-resistant gastric cancers. In summary, compound 10 could be a novel alternative therapeutic strategy for HER2-overexpressing cancers, overcoming the limitations of trastuzumab.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- College of Pharmacy and Graduate School of Pharmaceutical Sciences, Ewha Womans University, Seoul, Republic of Korea.
- College of Pharmacy, CHA University, Pocheon, Republic of Korea.
ORCID-Profile: Youngjoo Kwon
Förderung
- National Research Foundation of Korea
- Korea Basic Science Institute
Zitieren
APA
Hwang, S. Y., Jeon, K. H., Lee, H. J., Moon, I., Jung, S., Kim, S. A., Jo, H., Park, S., Ahn, M., Kwak, S. Y., Na, Y., & Kwon, Y. (2024). Synthesis and biological assessment of chalcone and pyrazoline derivatives as novel inhibitor for ELF3-MED23 interaction. eLife. https://doi.org/10.7554/elife.97051
Vancouver
Hwang SY, Jeon KH, Lee HJ, Moon I, Jung S, Kim SA, et al. Synthesis and biological assessment of chalcone and pyrazoline derivatives as novel inhibitor for ELF3-MED23 interaction. eLife. 2024. doi:10.7554/elife.97051
BibTeX
@article{Hwang2024,
author = {Hwang, Soo-Yeon and Jeon, Kyung-Hwa and Lee, Hwa-Jong and Moon, Inhye and Jung, Sehyun and Kim, Seul-Ah and Jo, Hyunji and Park, Seojeong and Ahn, Misun and Kwak, Soo-Yeon and Na, Younghwa and Kwon, Youngjoo},
title = {Synthesis and biological assessment of chalcone and pyrazoline derivatives as novel inhibitor for ELF3-MED23 interaction},
journal = {eLife},
year = {2024},
doi = {10.7554/elife.97051}
}
EUVIMED